A Phase I/II, pharmacokinetics and dose-finding study of M121101 in patients with pincer nail

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224657

Enrollment

Registered

2019-04-22

Start date

2019-04-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pincer nail

Interventions

investigational material(s) Generic name etc : M1211 INN of investigational material : - Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investigational materi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pincer nail patients

Exclusion criteria

Exclusion criteria: (1)Subjects with complications of any of ingrown nail, onychomycosis, nail psoriasis, onychogryphosis, and pachyonychia at the application site (2)Subjects with the clinically significant liver, kidney, heart, or lung diseases that require hospitalization

Design outcomes

Primary

Measure	Time frame
efficacy The clinical effect at the end of the treatment period safety Adverse events, Laboratory test results pharmacokinetics plasma concentration of M1211	—

Secondary

Measure	Time frame
other -	—

Countries

Japan

Contacts

Public ContactClinical Trials Information

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026